Digital learnings and modality visions: Novartis’ CEO on where R&D is headed

By C. Simone Fishburn, Editor in Chief

While the most high profile event on Novartis’ digital health front last year was arguably its retreat from the Pear deal, CEO Vasant Narasimhan still counts going big on data and digital science as one of the pharma’s top priorities. The lesson, he says, is that commercialization of digital therapies won’t fit into the traditional paradigm and will require a completely new go-to-market model...